These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 15289458)

  • 1. N-terminal polyubiquitination and degradation of the Arf tumor suppressor.
    Kuo ML; den Besten W; Bertwistle D; Roussel MF; Sherr CJ
    Genes Dev; 2004 Aug; 18(15):1862-74. PubMed ID: 15289458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ubiquitination of, and sumoylation by, the Arf tumor suppressor.
    den Besten W; Kuo ML; Tago K; Williams RT; Sherr CJ
    Isr Med Assoc J; 2006 Apr; 8(4):249-51. PubMed ID: 16671360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosome biogenesis and cell proliferation.
    Itahana K; Bhat KP; Jin A; Itahana Y; Hawke D; Kobayashi R; Zhang Y
    Mol Cell; 2003 Nov; 12(5):1151-64. PubMed ID: 14636574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mdm-2 and ubiquitin-independent p53 proteasomal degradation regulated by NQO1.
    Asher G; Lotem J; Sachs L; Kahana C; Shaul Y
    Proc Natl Acad Sci U S A; 2002 Oct; 99(20):13125-30. PubMed ID: 12232053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The MDM2-p53 interaction.
    Moll UM; Petrenko O
    Mol Cancer Res; 2003 Dec; 1(14):1001-8. PubMed ID: 14707283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclin G1 has growth inhibitory activity linked to the ARF-Mdm2-p53 and pRb tumor suppressor pathways.
    Zhao L; Samuels T; Winckler S; Korgaonkar C; Tompkins V; Horne MC; Quelle DE
    Mol Cancer Res; 2003 Jan; 1(3):195-206. PubMed ID: 12556559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo.
    Xirodimas D; Saville MK; Edling C; Lane DP; Laín S
    Oncogene; 2001 Aug; 20(36):4972-83. PubMed ID: 11526482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation.
    Rodriguez MS; Desterro JM; Lain S; Lane DP; Hay RT
    Mol Cell Biol; 2000 Nov; 20(22):8458-67. PubMed ID: 11046142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sumoylation induced by the Arf tumor suppressor: a p53-independent function.
    Tago K; Chiocca S; Sherr CJ
    Proc Natl Acad Sci U S A; 2005 May; 102(21):7689-94. PubMed ID: 15897463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ubiquitin ligase COP1 is a critical negative regulator of p53.
    Dornan D; Wertz I; Shimizu H; Arnott D; Frantz GD; Dowd P; O'Rourke K; Koeppen H; Dixit VM
    Nature; 2004 May; 429(6987):86-92. PubMed ID: 15103385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor.
    Chen D; Kon N; Li M; Zhang W; Qin J; Gu W
    Cell; 2005 Jul; 121(7):1071-83. PubMed ID: 15989956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MDM2 promotes p21waf1/cip1 proteasomal turnover independently of ubiquitylation.
    Jin Y; Lee H; Zeng SX; Dai MS; Lu H
    EMBO J; 2003 Dec; 22(23):6365-77. PubMed ID: 14633995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MDM2 promotes ubiquitination and degradation of MDMX.
    Pan Y; Chen J
    Mol Cell Biol; 2003 Aug; 23(15):5113-21. PubMed ID: 12860999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p14ARF is a component of the p53 response following ionizing irradiation of normal human fibroblasts.
    Khan S; Guevara C; Fujii G; Parry D
    Oncogene; 2004 Aug; 23(36):6040-6. PubMed ID: 15195142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A post-ubiquitination role for MDM2 and hHR23A in the p53 degradation pathway.
    Brignone C; Bradley KE; Kisselev AF; Grossman SR
    Oncogene; 2004 May; 23(23):4121-9. PubMed ID: 15064742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function.
    Korgaonkar C; Hagen J; Tompkins V; Frazier AA; Allamargot C; Quelle FW; Quelle DE
    Mol Cell Biol; 2005 Feb; 25(4):1258-71. PubMed ID: 15684379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo.
    Midgley CA; Desterro JM; Saville MK; Howard S; Sparks A; Hay RT; Lane DP
    Oncogene; 2000 May; 19(19):2312-23. PubMed ID: 10822382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topors functions as an E3 ubiquitin ligase with specific E2 enzymes and ubiquitinates p53.
    Rajendra R; Malegaonkar D; Pungaliya P; Marshall H; Rasheed Z; Brownell J; Liu LF; Lutzker S; Saleem A; Rubin EH
    J Biol Chem; 2004 Aug; 279(35):36440-4. PubMed ID: 15247280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypophosphorylation of Mdm2 augments p53 stability.
    Blattner C; Hay T; Meek DW; Lane DP
    Mol Cell Biol; 2002 Sep; 22(17):6170-82. PubMed ID: 12167711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53.
    Honda R; Yasuda H
    EMBO J; 1999 Jan; 18(1):22-7. PubMed ID: 9878046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.